Valneva SE (VLA.PA)
EUR 1.83
(2.93%)
EUR 1.83
(2.93%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 153.71 Million EUR | -57.46% |
| 2022 | 361.3 Million EUR | 3.8% |
| 2021 | 348.08 Million EUR | 215.52% |
| 2020 | 110.32 Million EUR | -12.58% |
| 2019 | 126.19 Million EUR | 11.64% |
| 2018 | 113.03 Million EUR | 7.35% |
| 2017 | 105.29 Million EUR | 11.94% |
| 2016 | 94.06 Million EUR | 20.04% |
| 2015 | 78.35 Million EUR | 112.22% |
| 2014 | 36.92 Million EUR | 21.28% |
| 2013 | 30.44 Million EUR | 787.35% |
| 2012 | 3.43 Million EUR | -66.57% |
| 2011 | 10.26 Million EUR | 22.25% |
| 2010 | 8.39 Million EUR | 171.16% |
| 2009 | 3.09 Million EUR | -9.42% |
| 2008 | 3.41 Million EUR | 294.69% |
| 2007 | 866 Thousand EUR | -62.82% |
| 2006 | 2.32 Million EUR | -22.65% |
| 2005 | 3.01 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 38.06 Million EUR | 16.2% |
| 2024 Q1 | 32.75 Million EUR | -21.83% |
| 2023 Q2 | 40.23 Million EUR | 20.08% |
| 2023 Q4 | 41.89 Million EUR | 10.05% |
| 2023 Q3 | 38.07 Million EUR | -5.38% |
| 2023 FY | 153.71 Million EUR | -57.46% |
| 2023 Q1 | 33.5 Million EUR | -69.92% |
| 2022 Q4 | 111.4 Million EUR | -28.9% |
| 2022 Q1 | 21.84 Million EUR | -92.15% |
| 2022 FY | 361.3 Million EUR | 3.8% |
| 2022 Q3 | 156.67 Million EUR | 119.51% |
| 2022 Q2 | 71.37 Million EUR | 226.69% |
| 2021 Q2 | 24.28 Million EUR | 4.61% |
| 2021 Q3 | 22.34 Million EUR | -7.99% |
| 2021 Q4 | 278.23 Million EUR | 1145.13% |
| 2021 FY | 348.08 Million EUR | 215.52% |
| 2021 Q1 | 23.21 Million EUR | -54.9% |
| 2020 Q4 | 51.47 Million EUR | 370.46% |
| 2020 Q3 | 10.94 Million EUR | -13.76% |
| 2020 Q2 | 12.68 Million EUR | -63.98% |
| 2020 FY | 110.32 Million EUR | -12.58% |
| 2020 Q1 | 35.22 Million EUR | -21.39% |
| 2019 Q4 | 44.8 Million EUR | 66.65% |
| 2019 Q1 | 34.85 Million EUR | 0.43% |
| 2019 Q2 | 19.65 Million EUR | -43.61% |
| 2019 Q3 | 26.88 Million EUR | 36.79% |
| 2019 FY | 126.19 Million EUR | 11.64% |
| 2018 Q1 | 32.08 Million EUR | 10.82% |
| 2018 FY | 113.03 Million EUR | 7.35% |
| 2018 Q4 | 34.7 Million EUR | 79.25% |
| 2018 Q3 | 19.36 Million EUR | -27.98% |
| 2018 Q2 | 26.88 Million EUR | -16.2% |
| 2017 Q1 | 28.44 Million EUR | 9.27% |
| 2017 FY | 105.29 Million EUR | 11.94% |
| 2017 Q4 | 28.94 Million EUR | 28.76% |
| 2017 Q3 | 22.48 Million EUR | -11.54% |
| 2017 Q2 | 25.41 Million EUR | -10.65% |
| 2016 Q1 | 23.74 Million EUR | 13.36% |
| 2016 FY | 94.06 Million EUR | 20.04% |
| 2016 Q4 | 26.03 Million EUR | 41.51% |
| 2016 Q3 | 18.39 Million EUR | -28.95% |
| 2016 Q2 | 25.89 Million EUR | 9.02% |
| 2015 Q3 | 20.2 Million EUR | 8.68% |
| 2015 Q4 | 20.94 Million EUR | 3.68% |
| 2015 FY | 78.35 Million EUR | 112.22% |
| 2015 Q2 | 18.59 Million EUR | -0.11% |
| 2015 Q1 | 18.61 Million EUR | 61.92% |
| 2014 FY | 36.92 Million EUR | 21.28% |
| 2014 Q4 | 11.49 Million EUR | 3.81% |
| 2014 Q3 | 11.07 Million EUR | 37.16% |
| 2014 Q2 | 8.07 Million EUR | 28.55% |
| 2014 Q1 | 6.28 Million EUR | -29.26% |
| 2013 Q3 | 13.82 Million EUR | 97.37% |
| 2013 FY | 30.44 Million EUR | 787.35% |
| 2013 Q1 | 737 Thousand EUR | -17.65% |
| 2013 Q2 | 7 Million EUR | 850.47% |
| 2013 Q4 | 8.87 Million EUR | -35.79% |
| 2012 Q4 | 895 Thousand EUR | -13.28% |
| 2012 Q3 | 1.03 Million EUR | 0.0% |
| 2012 FY | 3.43 Million EUR | -66.57% |
| 2011 FY | 10.26 Million EUR | 22.25% |
| 2010 FY | 8.39 Million EUR | 171.16% |
| 2009 FY | 3.09 Million EUR | -9.42% |
| 2008 FY | 3.41 Million EUR | 294.69% |
| 2007 FY | 866 Thousand EUR | -62.82% |
| 2006 FY | 2.32 Million EUR | -22.65% |
| 2005 FY | 3.01 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -3212.759% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -3226.38% |
| Adocia SA | 2.15 Million EUR | -7049.395% |
| Aelis Farma SA | 9.05 Million EUR | -1597.725% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -4778.197% |
| genOway Société anonyme | 20.04 Million EUR | -666.782% |
| IntegraGen SA | 12.53 Million EUR | -1126.024% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -51131.527% |
| Neovacs S.A. | 533.41 Thousand EUR | -28716.75% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -9041.28% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -776380.097% |
| Sensorion SA | 4.74 Million EUR | -3140.774% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -51771.725% |
| TME Pharma N.V. | 17 Thousand EUR | -904088.235% |
| Valbiotis SA | 4.73 Million EUR | -3147.665% |
| TheraVet SA | 1.07 Million EUR | -14158.271% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -8439.556% |
| argenx SE | 1.13 Billion EUR | 86.449% |
| BioSenic S.A. | 543 Thousand EUR | -28207.919% |
| Celyad Oncology SA | 102 Thousand EUR | -150598.039% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 35.88% |
| Genfit S.A. | 28.56 Million EUR | -438.113% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -7265.213% |
| Innate Pharma S.A. | 51.9 Million EUR | -196.164% |
| Inventiva S.A. | 17.47 Million EUR | -779.51% |
| MaaT Pharma SA | 2.22 Million EUR | -6799.102% |
| MedinCell S.A. | 9.16 Million EUR | -1578.079% |
| Nanobiotix S.A. | 30.05 Million EUR | -411.385% |
| Onward Medical N.V. | 532 Thousand EUR | -28793.233% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -983.119% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -6802.2% |
| Oxurion NV | 263 Thousand EUR | -58345.627% |
| Pharming Group N.V. | 245.31 Million EUR | 37.341% |
| Poxel S.A. | 1.98 Million EUR | -7659.313% |
| GenSight Biologics S.A. | 1.26 Million EUR | -12031.965% |
| Transgene SA | 1.18 Million EUR | -12882.432% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 97.073% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 4346.188% |